Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

10-Day Decitabine Versus Intensive Chemotherapy Followed By Transplantation in Fit AML Patients Aged ≥60 Years: Health-Related Quality of Life Outcomes of the Randomized Phase III Trial AML21 of the EORTC Leukemia Group, Gimema, Celg, and Gmds-SG

Blood (2022) 140 (Supplement 1): 1281–1283.

https://doi.org/10.1182/blood-2022-166544

Published: 2022

Journal Articles

Fetal Hemoglobin (HbF) Induction during Initial Decitabine (DAC) Treatment of Elderly High-Risk MDS and AML Patients: A Potential Dynamic Biomarker for Outcome

Julia Stomper, Gabriele Ihorst, Stefan Suciu, Philipp Nikolaus Sander, Heiko Becker, P.W. Wijermans, Emmanuel Bissé, Rainer Claus, Michael Lübbert

Blood (2017) 130 (Supplement 1): 4261.

https://doi.org/10.1182/blood.V130.Suppl_1.4261.4261

Published: 2017

Journal Articles

Escalated Dose Bortezomib Once Weekly Combined with Lenalidomide and Dexamethasone (eVRD) Followed by Lenalidomide Maintenance in First Relapse of Multiple Myeloma (MM). the HOVON 86 Phase 2 Trial

Pieter Sonneveld, MD, Okke de Weerdt, Mark-David Levin, Wendimagegn Ghidey, Edo Vellenga, Saskia K Klein, Jeanette Doorduyn, Marie José Kersten, P.W. Wijermans, MD, PhD, Henk Lokhorst, MD

Blood (2012) 120 (21): 1853.

https://doi.org/10.1182/blood.V120.21.1853.1853

Published: 2012

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) Improves Outcome As Compared to Conventional Consolidation in Patients Aged 40–60 Years with AML in CR1 with Apparent Greater Benefit for Reduced Intensity Rather Than Myeloablative Conditioning

Blood (2011) 118 (21): 159.

https://doi.org/10.1182/blood.V118.21.159.159

Published: 2011

Journal Articles

Platelet Doubling After the First Azacitidine Cycle Is a Promising Predictor for Response in MDS, CMML and AML Patients in the Dutch Azacitidine Compassionate Patient Named Program,

Blood (2011) 118 (21): 3841.

https://doi.org/10.1182/blood.V118.21.3841.3841

Published: 2011

Journal Articles

A Phase 2 Multicenter Study of Siltuximab, An Anti-IL-6 Monoclonal Antibody, in Patients with Relapsed or Refractory Multiple Myeloma,

Peter M. Voorhees, MD, Robert F Manges, MD, Pieter Sonneveld, MD, PhD, Sundar Jagannath, MD, George Somlo, MD, Amrita Krishnan, MD, Suzanne Lentzsch, MD, PhD, Richard C Frank, MD, Sonja Zweegman, MD, PhD, P.W. Wijermans, MD, PhD, Britte Rijnbeek, Xiang Qin, PhD, Mark J. Cornfeld, MD, MPH, Hong Xie, MD, MS, MBA, Sheeba K. Thomas, MD

Blood (2011) 118 (21): 3971.

https://doi.org/10.1182/blood.V118.21.3971.3971

Published: 2011

Journal Articles

Achievement of Complete Response Is a Strong Prognostic Factor In Elderly Newly Diagnosed Myeloma: Retrospective Analysis of 1175 Patients

Blood (2010) 116 (21): 1949.

https://doi.org/10.1182/blood.V116.21.1949.1949

Published: 2010

Journal Articles

High Dose Intensive Chemotherapy, as Is Standard in Childhood Leukemia, Is Feasible and Efficacious in Adult Patients with Acute Lymphoblastic Leukemia (ALL) up to the Age of 40: Results From the Dutch-Belgian HOVON-70 Study.

A. W Rijneveld, B. van der Holt, S. M. G. J. Daenen, B. J. Biemond, A. A van de Loosdrecht, O. de Weerdt, P. Muus, J. Maertens, V. Mattijssen, H. Demuynck, Mcjc Legdeur, P.W. Wijermans, S. Wittebol, F. Spoelstra, A. W. Dekker, G.J. Ossenkoppele, J. J. Cornelissen, R. Willemze

Blood (2009) 114 (22): 323.

https://doi.org/10.1182/blood.V114.22.323.323

Published: 2009

Journal Articles

Mobilisation of Autologous Stem Cells Using a Single Fixed Dose Injection of Pegfilgrastim; Feasibility in Extensively Pre-Treated Lymphoma and Myeloma Patients.

Paula F. Ypma, MD, Arif A. Muradin, P.W. Wijermans, MD,PhD

Blood (2006) 108 (11): 5220.

https://doi.org/10.1182/blood.V108.11.5220.5220

Published: 2006

Journal Articles

Efficacy of Decitabine in the Treatment of Patients with Chronic Myelomonocytic Leukemia (CMML).

P.W. Wijermans, MD, Michael Lübbert, MD, PhD, Maria R. Baer, MD, James L. Slack, MD

Blood (2006) 108 (11): 2676.

https://doi.org/10.1182/blood.V108.11.2676.2676

Published: 2006

Journal Articles

Phase III Trial of 2-Weekly CHOP with Rituximab for Aggressive B-Cell Non-Hodgkin’s Lymphoma in Elderly Patients.

Pieter Sonneveld, MD, Wim van Putten, MsC, Douwe Biesma, MD, Harald Holte, MD, Marinus van Marwijk Kooij, MD, Mark Henri H. Kramer, MD, P.W. Wijermans, MD, Monique Steijaert, Gustaaf W. van Imhoff, MD, P.J. Lugtenburg, MD, P.C. Huijgens, MD, Mikael Eriksson, MD

Blood (2006) 108 (11): 210.

https://doi.org/10.1182/blood.V108.11.210.210

Published: 2006

Journal Articles

Isovolemic Erythrocytapheresis; Fixed Versus Patient Tailored Volume Exchange in Patients with Polycythemia or Hemochromatosis.

P.W. Wijermans, MD, PhD, L. van Egmond, P.F. Ypma, MD, M.R. Schipperus, MD PhD, Jean-Louis Kerkhoffs, MD, L.H. Bohmer, MD

Blood (2006) 108 (11): 4894.

https://doi.org/10.1182/blood.V108.11.4894.4894

Published: 2006

Journal Articles

Response Rates of Phase 2 and Phase 3 Trials of Decitabine (DAC) in Patients with Myelodysplastic Syndromes (MDS).

Hussain I. Saba, MD, PhD, Michael Lübbert, MD, PhD, P.W. Wijermans, MD

Blood (2005) 106 (11): 2515.

https://doi.org/10.1182/blood.V106.11.2515.2515

Published: 2005

NARROW

10-Day Decitabine Versus Intensive Chemotherapy Followed By Transplantation in Fit AML Patients Aged ≥60 Years: Health-Related Quality of Life Outcomes of the Randomized Phase III Trial AML21 of the EORTC Leukemia Group, Gimema, Celg, and Gmds-SG

Fetal Hemoglobin (HbF) Induction during Initial Decitabine (DAC) Treatment of Elderly High-Risk MDS and AML Patients: A Potential Dynamic Biomarker for Outcome

Escalated Dose Bortezomib Once Weekly Combined with Lenalidomide and Dexamethasone (eVRD) Followed by Lenalidomide Maintenance in First Relapse of Multiple Myeloma (MM). the HOVON 86 Phase 2 Trial

Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) Improves Outcome As Compared to Conventional Consolidation in Patients Aged 40–60 Years with AML in CR1 with Apparent Greater Benefit for Reduced Intensity Rather Than Myeloablative Conditioning

Platelet Doubling After the First Azacitidine Cycle Is a Promising Predictor for Response in MDS, CMML and AML Patients in the Dutch Azacitidine Compassionate Patient Named Program,

A Phase 2 Multicenter Study of Siltuximab, An Anti-IL-6 Monoclonal Antibody, in Patients with Relapsed or Refractory Multiple Myeloma,

Achievement of Complete Response Is a Strong Prognostic Factor In Elderly Newly Diagnosed Myeloma: Retrospective Analysis of 1175 Patients

High Dose Intensive Chemotherapy, as Is Standard in Childhood Leukemia, Is Feasible and Efficacious in Adult Patients with Acute Lymphoblastic Leukemia (ALL) up to the Age of 40: Results From the Dutch-Belgian HOVON-70 Study.

Mobilisation of Autologous Stem Cells Using a Single Fixed Dose Injection of Pegfilgrastim; Feasibility in Extensively Pre-Treated Lymphoma and Myeloma Patients.

Efficacy of Decitabine in the Treatment of Patients with Chronic Myelomonocytic Leukemia (CMML).

Phase III Trial of 2-Weekly CHOP with Rituximab for Aggressive B-Cell Non-Hodgkin’s Lymphoma in Elderly Patients.

Isovolemic Erythrocytapheresis; Fixed Versus Patient Tailored Volume Exchange in Patients with Polycythemia or Hemochromatosis.

Response Rates of Phase 2 and Phase 3 Trials of Decitabine (DAC) in Patients with Myelodysplastic Syndromes (MDS).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only